Comparative Pharmacology
Head-to-head clinical analysis: ADRUCIL versus HYDROXYUREA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADRUCIL versus HYDROXYUREA.
ADRUCIL vs HYDROXYUREA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluorouracil (5-FU) is a pyrimidine analog that inhibits thymidylate synthase, interfering with DNA synthesis. It is metabolized to its active metabolites, which incorporate into RNA and DNA, causing cytotoxicity primarily in S-phase cells.
Inhibits ribonucleotide reductase, leading to decreased DNA synthesis and cell cycle arrest in S phase; also increases fetal hemoglobin production by inducing nitric oxide and altering erythroid progenitor signaling.
12 mg/kg IV bolus daily for 4 days, then if no toxicity, 6 mg/kg IV on days 6, 8, 10, and 12; or 15 mg/kg IV weekly; or 500-600 mg/m2 IV every 3-4 weeks.
Oral: 15-20 mg/kg once daily (rounded to nearest 500 mg) for myeloproliferative disorders (e.g., essential thrombocythemia); 80 mg/kg every 3 days (as 35 mg/kg single dose) for sickle cell disease.
None Documented
None Documented
Clinical Note
moderateHydroxyurea + Digoxin
"Hydroxyurea may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateHydroxyurea + Digitoxin
"Hydroxyurea may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateHydroxyurea + Deslanoside
"Hydroxyurea may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateHydroxyurea + Acetyldigitoxin
"Hydroxyurea may decrease the cardiotoxic activities of Acetyldigitoxin."
Biphasic elimination: initial t1/2α ~10-20 minutes, terminal t1/2β ~20-24 hours. Accumulation occurs with continuous infusion.
Terminal half-life: 3.5–4.5 hours; clinical context: hematologic effects persist for 24-48 hours due to irreversible inhibition of ribonucleotide reductase.
Primarily hepatic metabolism; renal excretion of metabolites accounts for ~60-80% of the dose. Unchanged fluorouracil excreted renally is <10%. Fecal excretion is minimal (<5%).
Renal: approximately 80% (30-60% unchanged; remainder as metabolites). Fecal: <10%.
Category C
Category A/B
Antimetabolite
Antimetabolite